At Fortress Biotech, our diversified product pipeline includes over 25 candidates in various phases of pre-clinical and clinical development. These product candidates are developed in collaboration with our partner companies and span several large-market therapeutic areas, including oncology, rare diseases, gene therapy and more. In addition, Fortress has several marketed dermatology products.
Ximino® is the first and only extended-release minocycline with Capsular Minotab Technology indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.
Learn MoreAcne
93% Journey Medical Corporation
Targadox® is a 50 mg immediate-release doxycycline hyclate coated tablet that is indicated as adjunctive therapy for severe acne.
Learn MoreAcne
93% Journey Medical Corporation
Exelderm® is an antifungal agent available as both a cream and solution.
Exelderm® Cream 1.0% is an antifungal agent indicated for the treatment of tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagro-phytes, Epidermophyton floccosum, and Microsporum canis,* and for the treatment of tinea versicolor.
*Efficacy for this organism in the organ system was studied in fewer than 10 infections.
Exelderm® Solution 1.0% is a broad-spectrum antifungal agent indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athlete’s foot).
Learn MoreFungal Infections
93% Journey Medical Corporation
Ceracade® is formulated for the treatment of dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatitis.
Learn MoreEczema
93% Journey Medical Corporation
Luxamend® wound cream is a water-based emulsion formulated for the treatment of superficial wounds, minor abrasions, dermal ulcers, donor sites, first- and second-degree burns, and radiation dermatitis.
Learn MoreWounds
93% Journey Medical Corporation
IV Tramadol is intended for the management of moderate to moderately severe postoperative pain.
View Clinical Trial View Clinical Trial View Clinical TrialPost-Surgical Acute Pain
Many patients who undergo surgical procedures experience severe postoperative pain. IV Tramadol is being developed as a potential treatment for pain management following surgery, including abdominoplasty and bunionectomy.
Abdominoplasty, or more commonly referred to as a “tummy tuck,” is a cosmetic surgical procedure in which excess skin and fat is removed from the abdomen, resulting in a smoother and firmer abdomen. A bunionectomy is a surgical procedure to remove a bunion from a patient’s foot. Depending on the complexity of these surgeries, some patients will experience severe postoperative pain.
29% Avenue; 10-20% CVR Royalty on Gross Profits
CUTX-101 is a copper histidinate injection for the treatment of Menkes disease.
View Clinical Trial View Clinical TrialMenkes Disease
Menkes disease is an X-linked genetic disorder of copper transport caused by mutations of the ATP7A gene. Copper is an essential trace element required for human development and health. In Menkes disease, patients are born without the ability to absorb copper from diet, leading to severe developmental delays and significant neurological symptoms. Without treatment, Menkes disease could lead to death by three years of age. There is currently no FDA-approved therapy for the treatment of Menkes disease.
79% Cyprium; 4.5% Royalty
MB-107 is a novel lentiviral gene therapy intended for the treatment of X-linked severe combined immunodeficiency (XSCID).
View Clinical Trial View Clinical TrialNewly Diagnosed X-Linked Severe Combined Immunodeficiency (XSCID)
XSCID, also known as bubble boy disease, is the most common form of severe combined immunodeficiency, affecting approximately one in 225,000 newborns in the U.S. per year. There are also ~400 patients living with XSCID post-transplant in the U.S. and ~650 patients living with XSCID post-transplant in high- and mid-income ex-U.S. countries.
31% Mustang; 4.5% Royalty
MB-207 is a novel lentiviral gene therapy intended for the treatment of X-linked severe combined immunodeficiency (XSCID).
View Clinical Trial View Clinical TrialPreviously Transplanted X-Linked Severe Combined Immunodeficiency (XSCID)
XSCID, also known as bubble boy disease, is the most common form of severe combined immunodeficiency, affecting approximately one in 225,000 newborns in the U.S. per year. There are also ~400 patients living with XSCID post-transplant in the U.S. and ~650 patients living with XSCID post-transplant in high- and mid-income ex-U.S. countries.
31% Mustang; 4.5% Royalty
Cosibelimab is a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 (PD-1) and B7.1 receptors.
View Clinical TrialcSCC
Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer in the United States. cSCC starts in squamous cells within the surface of the skin, and upon progression, can invade deeper layers of the skin or spread to lymph nodes or other parts of the body. Surgery is the first option for patients with cSCC. In advanced stages, some patients will be treated with radiation or systemic drug therapy; however, certain patients may not be able to be cured with surgery or radiation. It is estimated that 7,000 patients in the United States die each year from cSCC.
21% Checkpoint; 4.5% Royalty
CK-101 is a small-molecule, targeted anti-cancer agent for the treatment of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
View Clinical TrialFrontline NSCLC with EGFR Mutations
Lung cancer is the leading cause of cancer death among men and women. There are two main types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The American Cancer Society estimates that roughly 80% to 85% of lung cancers are NSCLC. Approximately 20% of newly diagnosed NSCLC patients have activating mutations in EGFR, which can be selectively targeted with an EGFR inhibitor.
21% Checkpoint; 4.5% Royalty
CAEL-101 is a first-in-class anti-amyloid antibody designed to improve organ function by reducing or eliminating amyloid deposits in patients with amyloid light chain (AL) amyloidosis.
View Clinical TrialAL Amyloidosis
AL amyloidosis is a rare systemic disorder caused by an abnormality of plasma cells in the bone marrow. Misfolded amyloid proteins produced by plasma cells cause buildup in and around tissues, nerves and organs, gradually affecting their function. This can cause progressive and widespread organ damage and high mortality rates.
43% Caelum
Triplex is a universal, multi-antigen T-cell immunotherapeutic vaccine for controlling cytomegalovirus (CMV) in stem cell and solid organ transplant recipients.
View Clinical Trial View Clinical Trial View Clinical TrialCytomegalovirus (CMV)
CMV is a common virus that is typically asymptomatic in healthy individuals but can cause life-threatening disease in those with weakened or uneducated immune systems. Patients undergoing allogeneic stem cell and solid organ transplantation are at particularly high risk of experiencing complications associated with CMV.
CMV can be transmitted to seronegative transplant recipients through infected donor grafts or reactivated in seropositive transplant recipients (particularly those with low baseline immunity) as a result of their immune-suppressed condition. In either instance, CMV can cause severe and life-threatening complications, including pneumonia, gastroenteritis and retinitis.
81% Helocyte; 4.5% Royalty
CEVA 101 Pediatric is a clinical-stage cell therapy for the treatment of severe traumatic brain injury (TBI) in children.
View Clinical TrialTraumatic Brain Injury (TBI)
Pediatric severe TBIs are the leading cause of death and disability in children ages 1-14 years old. There are no effective therapies to treat secondary brain injury and the post-injury response of central nervous system apoptosis and neuroinflammation.
78% Cellvation; 4.5% Royalty
CEVA 101 Adult is a clinical-stage cell therapy for the treatment of severe traumatic brain injury (TBI) in adults.
View Clinical TrialTraumatic Brain Injury (TBI)
TBIs are associated with 33% of all trauma-related deaths. There are no effective therapies to treat secondary brain injury and the post-injury response of central nervous system apoptosis and neuroinflammation.
78% Cellvation; 4.5% Royalty
MB-102 is a chimeric antigen receptor (CAR) T therapy for acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk myelodysplastic syndrome (hrMDS).
View Clinical TrialAML, BPDCN, and hrMDS
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells characterized by rapid growth of abnormal white blood cells that accumulate in the bone marrow. Although AML is rare, there were an estimated 19,520 new U.S. cases of AML in 2018 with an estimated five-year survival rate of 25%. Current treatment of relapsed or refractory AML with chemotherapy or hematopoietic stem cell transplantation is associated with low rates of complete response and considerable complications.
BPDCN is an ultra-rare disease and aggressive blood cancer with 500-1,000 patients per year in the U.S. and a median overall survival of 9-12 months.
CD123 is overexpressed on AML blasts and leukemic stem cell-enriched cell subpopulations compared to normal hematopoietic stem cells and myeloid progenitors, making CD123 an attractive target for T cell-based adoptive immunotherapy.
31% Mustang; 4.5% Royalty
MB-101 is a chimeric antigen receptor (CAR) T therapy for glioblastoma (GBM).
View Clinical TrialGlioblastoma (GBM)
GBM is the most common brain and central nervous system (CNS) cancer, accounting for 45.2% of malignant primary brain and CNS tumors, 54% of all gliomas, and 16% of all primary brain and CNS tumors. There were an estimated 12,390 new GBM cases predicted in 2017 in the U.S. Malignant brain tumors are the most common cause of cancer-related deaths in adolescents and young adults aged 15-39 and the most common cancer occurring among 15-19-year-olds in the U.S. Although GBM is a rare disease (2-3 cases per 100,000 persons per year in the US and EU), it is quite lethal, with five-year survival rates historically under 10%. Standard of care therapy consists of maximal surgical resection, radiation and chemotherapy with temozolomide, which, while rarely curative, is shown to extend median overall survival from 4.5 to 15 months. GBM remains difficult to treat due to the inherent resistance of the tumor to conventional therapies.
31% Mustang; 4.5% Royalty
MB-104 is a novel second-generation CS1-specific chimeric antigen receptor (CAR) T cell therapy for multiple myeloma (MM).
View Clinical TrialMultiple Myeloma (MM)
MM is a type of blood cancer that develops within bone marrow and affects plasma cells. Normal plasma cells produce antibodies that attack infections and diseases. When plasma cells become cancerous, however, they accumulate in the bone marrow and can cause severe pain and damage to the bone marrow. In addition, cancerous plasma cells will produce faulty antibodies, which make it harder for the body to fight off infections and diseases. Despite great advances in treatment, MM remains an uncured malignancy of plasma cells.
31% Mustang; 4.5% Royalty
MB-106 is a CD20-specific chimeric antigen receptor (CAR) T Program for B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
View Clinical TrialB-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (CLL)
There are several forms of NHL, including follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma and small lymphocytic lymphoma, which account collectively for ~45% of all cases of NHL. Most types of NHL are incurable with available therapies, except for allogenic hematopoietic stem cell transplant (allo-SCT). More than 70,000 new cases of B-cell NHL are diagnosed each year in the United States, and more than 19,000 patients die annually due to this group of diseases.
31% Mustang; 4.5% Royalty
MB-103 is a second-generation HER2-specific chimeric antigen receptor (CAR) T cell therapy for the treatment of glioblastoma (GBM) and metastatic breast cancer to brain.
View Clinical Trial View Clinical TrialGBM and Metastatic Breast Cancer to Brain
GBM is the most common brain and central nervous system (CNS) cancer, accounting for 45.2% of malignant primary brain and CNS tumors, 54% of all gliomas and 16% of all primary brain and CNS tumors. There were an estimated 12,390 new GBM cases predicted in 2017 in the U.S. Malignant brain tumors are the most common cause of cancer-related deaths in adolescents and young adults aged 15-39 and the most common cancer occurring among 15-19-year-olds in the U.S. Although GBM is a rare disease (2-3 cases per 100,000 persons per year in the U.S. and E.U.), it is quite lethal, with five-year survival rates historically under 10%. Standard of care therapy consists of maximal surgical resection, radiation and chemotherapy with temozolomide, which, while rarely curative, is shown to extend median overall survival from 4.5 to 15 months. GBM remains difficult to treat due to the inherent resistance of the tumor to conventional therapies.
HER2/neu (HER2) is a growth-promoting protein on the outside of all breast cells. HER2-positive (HER2+) breast cancer cells tend to grow and spread faster than other breast cancers. Breast cancer is the most commonly diagnosed cancer in women, with over 40,000 women in the U.S. expected to die from advanced metastatic disease annually. Approximately 20% to 25% of breast cancers overexpress HER2, which is an established therapeutic target of both monoclonal antibodies (mAbs) and receptor tyrosine kinase inhibitors.
31% Mustang; 4.5% Royalty
MB-108 is a next-generation oncolytic virus (C134) that can replicate in tumor cells, but not in normal cells. Replication of MB-108 in the tumor itself not only kills the infected tumor cells but also causes the tumor cell to act as a factory to produce new virus.
View Clinical TrialGlioblastoma (GBM)
GBM is the most common brain and central nervous system (CNS) cancer, accounting for 45.2% of malignant primary brain and CNS tumors, 54% of all gliomas and 16% of all primary brain and CNS tumors. There were an estimated 12,390 new GBM cases predicted in 2017 in the U.S. Malignant brain tumors are the most common cause of cancer-related deaths in adolescents and young adults aged 15-39 and the most common cancer occurring among 15-19-year-olds in the U.S. Although GBM is a rare disease (2-3 cases per 100,000 persons per year in the US and EU), it is quite lethal, with five-year survival rates historically under 10%. Standard of care therapy consists of maximal surgical resection, radiation and chemotherapy with temozolomide, which, while rarely curative, is shown to extend median overall survival from 4.5 to 15 months. GBM remains difficult to treat due to the inherent resistance of the tumor to conventional therapies.
31% Mustang; 4.5% Royalty
MB-105 is a second-generation PSCA-specific chimeric antigen receptor (CAR) T cell therapy for prostate, pancreatic, gastric and bladder cancers.
View Clinical TrialProstate, Pancreatic, Gastric and Bladder Cancers
Prostate cancer has an annual incidence of 164,000, pancreatic cancer has an annual incidence of 55,000, gastric cancer has an annual incidence of 26,000 and bladder cancer has an annual incidence of 81,000.
31% Mustang; 4.5% Royalty
BAER-101 is a novel α2/3–subtype-selective GABA A positive allosteric modulator (“PAM”).
CNS Disorders
Central nervous system diseases, also known as central nervous system disorders, are a group of neurological disorders that affect the structure or function of the brain or spinal cord, which collectively form the central nervous system (CNS).
67% Baergic; 4.5% Royalty
AVTS-001 is an adeno-associated virus (AAV) gene therapy that restores lasting production of regulatory proteins, potentially providing a curative treatment for diseases with high unmet need.
AMD, PNH, and aHUS
62% Aevitas; 4.5% Royalty
Adeno-associated virus (AAV)-based ATP7A is a gene therapy intended for use in combination with CUTX-101 for the treatment of Menkes disease and related copper transport disorders.
Menkes Disease
Menkes disease is an X-linked genetic disorder of copper transport caused by mutations of the ATP7A gene. Copper is an essential trace element required for human development and health. In Menkes disease, patients are born without the ability to absorb copper from diet, leading to severe developmental delays and significant neurological symptoms. Without treatment, Menkes disease could lead to death by three years of age. Currently, there is no FDA-approved therapy for treatment of Menkes disease.
79% Cyprium; 4.5% Royalty
CK-103 is a BET inhibitor that is designed to inhibit BRD4, a member of the BET domain for cancer treatment.
Multiple Solid Tumors
21% Checkpoint; 4.5% Royalty
CEVA-102 is the first cell product produced by CEVA-D and is being developed for the treatment of severe traumatic brain injury (TBI) in adults and children.
Traumatic Brain Injury (TBI)
TBIs are associated with 33% of all trauma-related deaths. There are no effective therapies to treat secondary brain injury and the post-injury response of central nervous system apoptosis and neuroinflammation.
78% Cellvation; 4.5% Royalty
CK-302, an anti-GITR monoclonal antibody, is being developed as a novel treatment for patients with multiple solid tumors.
Multiple Solid Tumors
21% Checkpoint; 4.5% Royalty
CK-303, an anti-CAIX monoclonal antibody, is being developed as a treatment for multiple solid tumors in patients.
Multiple Solid Tumors
21% Checkpoint; 4.5% Royalty
ConVax is a universal recombinant modified vaccinia ankara viral vector vaccine designed to induce robust and durable humoral and cellular immune responses to cytomegalovirus (CMV).
Cytomegalovirus Prevention and Control
81% Helocyte; 4.5% Royalty
CEVA-D is a novel bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells without genetic manipulation, using wall shear stress (WSS) to suppress tumor necrosis factor-a (TNF-a) production by activated immune cells.
Traumatic Brain Injury (TBI)
TBIs are associated with 33% of all trauma-related deaths. There are no effective therapies to treat secondary brain injury and the post-injury response of central nervous system apoptosis and neuroinflammation.
78% Cellvation; 4.5% Royalty
Targeted PNA sequence delivery to displace native DNA/RNA
80% Oncogenuity; 4.5% Royalty
We have a library of valuable content and resources that provide in-depth knowledge on our product candidates and various therapeutic areas of interest.
View Publications